biocom

biocom

Photo by Jaron Nix on Unsplash

A new biopharmaceutical startup, ACELYRIN, that launched this week is on the hunt for new immunological therapies that it can bring to market.

The company just closed a round backed by Westlake Village BioPartners, a two-year-old venture capital fund that recently raised $500 million.

Read more Show less
Photo by Vladimir Solomyani on Unsplash

Westlake Village BioPartners, the two-year-old Los Angeles venture capital firm investing in life science and therapeutic companies, has raised two new funds totaling $500 million. The announcement Tuesday brings the firm to $820 million in capital to date.

The first fund, called Opportunity 1, carves out $70 million for Westlake to invest Series B or later-stage rounds for companies they incubated or invested in previously.

Meanwhile, Westlake Village BioPartners 2 Fund is a $430 million stash for incubating and investing in about 12 Series A startups. The VC firm will also use that fund for other Series B or late-round investments.

Read more Show less
Trending